- Investing.com
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Market Opportunities | Delve into Insmed's strategy in targeting underserved patient populations, potentially driving significant revenue growth and market leadership in rare diseases |
Financial Outlook | Analysts project EPS of -5.57 and -4.93 for the next two fiscal years, with price targets ranging from $80 to $109, reflecting strong growth potential |
Pipeline Potential | Explore Insmed's promising pipeline, including brensocatib for bronchiectasis, with projected U.S. sales of up to $3.8 billion by 2034 |
Rare Disease Pionee | Insmed's focus on serious and rare diseases positions it as a significant player in niche markets with high unmet medical needs and potential for premium pricing |
Metrics to compare | INSM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINSMPeersSector | |
---|---|---|---|---|
P/E Ratio | −18.4x | −3.5x | −0.5x | |
PEG Ratio | 1.42 | −0.11 | 0.00 | |
Price / Book | 188.1x | 3.0x | 2.6x | |
Price / LTM Sales | 48.9x | 27.8x | 3.2x | |
Upside (Analyst Target) | 13.0% | 145.7% | 45.4% | |
Fair Value Upside | Unlock | 11.5% | 6.9% | Unlock |